A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy

Summary

The purpose of this study is to compare the efficacy and safety of subcutaneous (SC) risankizumab and oral FUMADERM provided as study medication in participants with moderate to severe plaque psoriasis who are naïve to and candidates for systemic therapy.

Timeline

Start

2017-08-22

Primary completion

2018-07-06

Completion

2018-07-06

Outcome

Met primary endpoint

registry analysis (other test); Fumaderm vs Risankizumab; p < 0.001; Adjusted percentage difference 73.3 (95% CI 61.3 to 85.3); Cochran-Mantel-Haenszel NCT03255382 ↗

Drugs

Indications